The first patient has been randomized in the phase 1 REGENERATE MSA-101 clinical trial of AB-1005, a gene therapy being developed as a treatment for multiple system atrophy-parkinsonian type (MSA-P). Asklepios BioPharmaceutical, Inc. (AskBio)...
Truqap (capivasertib) by AstraZeneca has got the clearance in the United States for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker...
Swiss-based medical technology company MedAlliance has announced acquisition by Cordis for $1.13 billion. Cordis will play a pivotal role in the marketing, distribution, and global accessibility of MedAlliance's
Lupin Limited (Lupin) announced that the United States Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application for Ganirelix Acetate injection, 250 mcg/0.5 mL single-dose prefilled syringe, to market a generic...
The government aims to grow the pharmaceutical industry by about four times to $200 billion by 2030, Arunish Chawla, secretary, department of pharmaceuticals, said. The sector should be able to achieve the target through the help of industrial...
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) approved Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)...
SciBase Holding AB (SciBase), a leading provider of augmented intelligence-based skin diseases solutions, signed a partnership agreement with the Skin and Cancer Institute to trial Nevisense in many of their California sites. The Skin and...
Astellas Pharma Inc. has agreed to buy Propella Therapeutics, Inc. for roughly $175 million. The acquisition is planned to take place during Astellas' fiscal year 2023, which will expire on March 31, 2024. PRL-02 (abiraterone decanoate), a...
voke Pharma, Inc announced that the US Patent and Trademark Office (USPTO) issued US Patent No. 11,813,231 titled "Nasal Formulations of Metoclopramide" pertaining to the company's commercially available and FDA-approved nasal formulation of...
Imfinzi (durvalumab), manufactured by AstraZeneca, has been licensed in China for the first-line treatment of adults with locally advanced or metastatic biliary tract cancer (BTC) in conjunction with chemotherapy (gemcitabine and cisplatin)...
, CDSCO.jpg)
